# Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

> **NCT03743298** · PHASE1 · RECRUITING · sponsor: **Aivita Biomedical, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** AV-MEL-1

## Key facts

- **NCT ID:** NCT03743298
- **Lead sponsor:** Aivita Biomedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-21
- **Primary completion:** 2024-05
- **Final completion:** 2026-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03743298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03743298, "Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03743298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*